Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.62 |
| ▸ | NPC1 | O15118 | 3/20 | 0.62 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | HTR2C | P28335 | 3/20 | 0.43 |
| ▸ | NOX1 | Q9Y5S8 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3624250 | 0.80 | RORC (0.40) | MEN1KMT2ANPC1GAAKDM4E | |
| SCHEMBL3624232 | 0.79 | MEN1 (0.96) | MEN1KMT2ANPC1GAAKDM4E | |
| SCHEMBL7296949 | 0.79 | HTR2C (0.48) | MEN1KMT2ANPC1GAAKDM4E | |
| SCHEMBL7296419 | 0.77 | DDB1 (0.55) | MEN1KMT2ANPC1GAAKDM4E | |
| SCHEMBL29746300 | 0.74 | GID4 (0.51) | MEN1KMT2ANPC1GAAKDM4E | |
| SCHEMBL28462830 | 0.74 | GID4 (0.51) | MEN1KMT2ANPC1GAAKDM4E | |
| SCHEMBL26613479 | 0.74 | GID4 (0.51) | MEN1KMT2ANPC1GAAKDM4E | |
| SCHEMBL16928582 | 0.71 | MEN1 (0.73) | MEN1KMT2ANPC1GAAKDM4E | |
| SCHEMBL15508303 | 0.71 | MEN1 (0.73) | MEN1KMT2ANPC1GAAKDM4E | |
| SCHEMBL2379977 | 0.70 | NPC1 (0.48) | MEN1KMT2ANPC1GAAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2392567-A1 | BENZOTHIAZINE DERIVATIVES AND THEIR USE AS LXR MODULATORS | Bristol-Myers Squibb Company (US) | 2011-12-07 | — | — | EP | disclosed |
| US-7741317-B2 | LXR modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-06-22 | — | — | US | disclosed |
| US-20070093470-A1 | LXR modulators | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093470-A1 | LXR modulators | NR1H2, NR1H3, RXRB | MEN1 3861/4885KMT2A 492/4885NPC1 105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.